Sample Prep Proving a Key Consideration in Clinical NGS Testing | GenomeWeb

SAN FRANCISCO — Increasingly, issues related to sample prep, not sequencing technology, are becoming the hurdle for developing clinical next-gen sequencing-based tests, researchers from Quest Diagnostics and the US Centers for Disease Control and Prevention said at this week's Molecular Medicine Tri Conference in San Francisco.

"A lot of the importance and value of a next-gen sequencing diagnostic test is in the sample prep," Jamie Platt, director of advanced sequencing at Quest Diagnostics, said during a presentation here.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.